{"id":{"repo_id":"marshall","oai_identifier":"oai:mds.marshall.edu:etd-3061"},"canonical_url":"https://search.ndltd.org/etd/marshall/oai:mds.marshall.edu:etd-3061","repository":{"repo_id":"marshall","name":"Marshall University","base_url":"https://mds.marshall.edu/do/oai/"},"display":{"title":"Developing curcumin analogues for treating breast cancer","abstract":"Breast cancer is still one of the most common types of cancer and one of the most common causes of cancer-related deaths in women around the world. Despite significant advances in early detection and treatment strategies, drug resistance, systemic toxicity, and poor outcomes in aggressive subtypes continue to limit the overall effectiveness of cancer therapy. Natural compounds have become promising anticancer agents because they can target many different things and are not very toxic. Curcumin has shown promise as an anticancer drug, but it cannot be used in the clinic because it does not absorb well, breaks down quickly, and does not stay stable for long. To address these constraints, synthetic curcumin analogues like FLLL12 and TEL109 have been engineered to exhibit superior pharmacological characteristics, including increased potency and stability. The current study seeks to assess the anticancer properties of curcumin analogues FLLL12 and TEL109 in breast cancer cell lines using Sulforhodamine B (SRB) assay to determine cytotoxicity and IC50 values, and the Annexin V/7-AAD assay with flow cytometry to assess apoptosis in a dose- and time-dependent manner (24, 48 and 72 hours). The findings highlight the potential of these curcumin analogues as effective therapeutic agents for breast cancer through enhanced antiproliferative and pro-apoptotic effects with reduced toxicity.","abstract_html":"Breast cancer is still one of the most common types of cancer and one of the most common causes of cancer-related deaths in women around the world. Despite significant advances in early detection and treatment strategies, drug resistance, systemic toxicity, and poor outcomes in aggressive subtypes continue to limit the overall effectiveness of cancer therapy. Natural compounds have become promising anticancer agents because they can target many different things and are not very toxic. Curcumin has shown promise as an anticancer drug, but it cannot be used in the clinic because it does not absorb well, breaks down quickly, and does not stay stable for long. To address these constraints, synthetic curcumin analogues like FLLL12 and TEL109 have been engineered to exhibit superior pharmacological characteristics, including increased potency and stability. The current study seeks to assess the anticancer properties of curcumin analogues FLLL12 and TEL109 in breast cancer cell lines using Sulforhodamine B (SRB) assay to determine cytotoxicity and IC50 values, and the Annexin V/7-AAD assay with flow cytometry to assess apoptosis in a dose- and time-dependent manner (24, 48 and 72 hours). The findings highlight the potential of these curcumin analogues as effective therapeutic agents for breast cancer through enhanced antiproliferative and pro-apoptotic effects with reduced toxicity.","abstract_has_math":false,"creators":["Nutalapati, Tulasi Laxmi"],"institution":null,"degree_name":"Pharmaceutical Sciences","degree_level":"Thesis","degree_discipline":"School of Pharmacy","degree_department":null,"school":null,"contributors":["Dr. A.R.M. Ruhul Amin","Dr. Cynthia B. Jones","Dr. Timothy Long"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-11-21T19:58:30Z","subjects":["Medicinal and Pharmaceutical Chemistry","Medicine and Health Sciences","Natural Products Chemistry and Pharmacognosy","Oncology","Pharmacy and Pharmaceutical Sciences","Women's Health","breast cancer","curcumin","synthetic curcumin analogues","antiproliferative effects","pro-apoptotic effects"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://mds.marshall.edu/etd/2056","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://mds.marshall.edu/etd/2056","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://mds.marshall.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Amds.marshall.edu%3Aetd-3061","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Dr. A.R.M. Ruhul Amin","Dr. Cynthia B. Jones","Dr. Timothy Long"]},{"key":"dc:creator","label":"Author","values":["Nutalapati, Tulasi Laxmi"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2026-04-22T07:00:00Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2026-01-01T08:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["School of Pharmacy"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Pharmaceutical Sciences"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Medicinal and Pharmaceutical Chemistry","Medicine and Health Sciences","Natural Products Chemistry and Pharmacognosy","Oncology","Pharmacy and Pharmaceutical Sciences","Women's Health","breast cancer","curcumin","synthetic curcumin analogues","antiproliferative effects","pro-apoptotic effects"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://mds.marshall.edu/etd/2056"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Breast cancer is still one of the most common types of cancer and one of the most common causes of cancer-related deaths in women around the world. Despite significant advances in early detection and treatment strategies, drug resistance, systemic toxicity, and poor outcomes in aggressive subtypes continue to limit the overall effectiveness of cancer therapy. Natural compounds have become promising anticancer agents because they can target many different things and are not very toxic. Curcumin has shown promise as an anticancer drug, but it cannot be used in the clinic because it does not absorb well, breaks down quickly, and does not stay stable for long. To address these constraints, synthetic curcumin analogues like FLLL12 and TEL109 have been engineered to exhibit superior pharmacological characteristics, including increased potency and stability. The current study seeks to assess the anticancer properties of curcumin analogues FLLL12 and TEL109 in breast cancer cell lines using Sulforhodamine B (SRB) assay to determine cytotoxicity and IC50 values, and the Annexin V/7-AAD assay with flow cytometry to assess apoptosis in a dose- and time-dependent manner (24, 48 and 72 hours). The findings highlight the potential of these curcumin analogues as effective therapeutic agents for breast cancer through enhanced antiproliferative and pro-apoptotic effects with reduced toxicity."]},{"key":"dc:title","label":"Title","values":["Developing curcumin analogues for treating breast cancer"]}]}],"canonical_facts":{"dc:contributor":["Dr. A.R.M. Ruhul Amin","Dr. Cynthia B. Jones","Dr. Timothy Long"],"dc:creator":["Nutalapati, Tulasi Laxmi"],"dc:date.available":["2026-04-22T07:00:00Z"],"dc:date.created":["2026-01-01T08:00:00Z"],"dc:description.abstract":["Breast cancer is still one of the most common types of cancer and one of the most common causes of cancer-related deaths in women around the world. Despite significant advances in early detection and treatment strategies, drug resistance, systemic toxicity, and poor outcomes in aggressive subtypes continue to limit the overall effectiveness of cancer therapy. Natural compounds have become promising anticancer agents because they can target many different things and are not very toxic. Curcumin has shown promise as an anticancer drug, but it cannot be used in the clinic because it does not absorb well, breaks down quickly, and does not stay stable for long. To address these constraints, synthetic curcumin analogues like FLLL12 and TEL109 have been engineered to exhibit superior pharmacological characteristics, including increased potency and stability. The current study seeks to assess the anticancer properties of curcumin analogues FLLL12 and TEL109 in breast cancer cell lines using Sulforhodamine B (SRB) assay to determine cytotoxicity and IC50 values, and the Annexin V/7-AAD assay with flow cytometry to assess apoptosis in a dose- and time-dependent manner (24, 48 and 72 hours). The findings highlight the potential of these curcumin analogues as effective therapeutic agents for breast cancer through enhanced antiproliferative and pro-apoptotic effects with reduced toxicity."],"dc:identifier":["https://mds.marshall.edu/etd/2056"],"dc:subject":["Medicinal and Pharmaceutical Chemistry","Medicine and Health Sciences","Natural Products Chemistry and Pharmacognosy","Oncology","Pharmacy and Pharmaceutical Sciences","Women's Health","breast cancer","curcumin","synthetic curcumin analogues","antiproliferative effects","pro-apoptotic effects"],"dc:title":["Developing curcumin analogues for treating breast cancer"],"thesis:degree_discipline":["School of Pharmacy"],"thesis:degree_level":["Thesis"],"thesis:degree_name":["Pharmaceutical Sciences"]},"updated_at":"2026-11-21T19:58:30Z"}